Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both

References

• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–2749.
   PubMed Web of Science ®Google Scholar
• Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28–38.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Despini G, Santagni S, et al. Effects of a combination of alpha lipoic acid and myo-inositol on insulin dynamics in overweight/obese patients with PCOS. Endocrinol Metab Syndr. 2014;3:3.
   Google Scholar
• Genazzani AD, Ricchieri F, Lanzoni C. Use of metformin in the treatment of polycystic ovary syndrome. Womens Health (Lond). 2010;6:577–593.
   PubMedGoogle Scholar
• Genazzani AD. Inositol as putative integrative treatment for PCOS. Reprod Biomed Online. 2016;33:770–780.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Chierchia E, Rattighieri E, et al. Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. Gynecol Endocrinol. 2010;26:684–689.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Battaglia C, Malavasi B, et al. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2004;81:114–119.
   PubMed Web of Science ®Google Scholar
• Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327:951–953.
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE, Jr, et al. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. 2006;29:300–305.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Lanzoni C, Ricchieri F, et al. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24:139–144.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Santagni S, Rattighieri E, et al. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol. 2014;30:438–443.
   PubMed Web of Science ®Google Scholar
• Dinicola S, Chiu TTY, Unfer V, et al. The rationale of the myo-inositol and d-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol. 2014;20:1–14.
   Google Scholar
• Lee WJ1, Song KH, Koh EH, et al. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun. 2005;332:885–891.
   PubMed Web of Science ®Google Scholar
• Shen QW, Zhu MJ, Tong J, et al. Ca2+/calmodulin-dependent protein kinase kinase is involved in AMP-activated protein kinase activation by alpha-lipoic acid in C2C12 myotubes. Am J Physiol Cell Physiol. 2007;293:C1395–C1403.
   PubMed Web of Science ®Google Scholar
• Masharani U, Gjerde C, Evans JL, et al. Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol. 2010;4:359–364.
   PubMedGoogle Scholar
• Gomes MB, Negrato CA. Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetol Metab Syndr. 2014;6:80.
   PubMed Web of Science ®Google Scholar
• Scaramuzza A, Giani E, Radaelli F, et al. Alpha-lipoic acid and antioxidant diet help to improve endothelial disfunction in adolescents with type 1 diabetes: a pilot study. J Diabetes Res. 2015;2015:474561.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Shefer K, Della Casa D, et al. Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. J Endocrinol Invest. 2018;41:583–590.
   PubMed Web of Science ®Google Scholar
• Madeira IR, Carvalho CN, Gazolla FM, et al. Cut-off point for Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) index established from Receiver Operating Characteristic (ROC) curve in the detection of metabolic syndrome in overweight prepubertal children. Arq Bras Endocrinol Metab. 2008;52:1466–1473.
   PubMedGoogle Scholar
• Genazzani AD, Prati A, Santagni S, et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol. 2012;28:969–973.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Petraglia F, Fabbri G, et al. Evidence of luteinizing hormone secretion in hypothalamic amenorrhea associated with weight loss. Fertil Steril. 1990;54:222–226.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Petraglia F, Benatti R, et al. Luteinizing hormone (LH) secretory burst duration is independent from LH, prolactin, or gonadal steroid plasma levels in amenorrheic women. J Clin Endocrinol Metab. 1991;72:1220–1225.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Petraglia F, Pianazzi F, et al. The concomitant release of androstenedione with cortisol and luteinizing hormone pulsatile releases distinguishes adrenal from ovarian hyperandrogenism. Gynecol Endocrinol. 1993;7:33–41.
   PubMed Web of Science ®Google Scholar
• Geloneze B, Vasques AC, Stabe CF, et al. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metabol. 2009;53:281–287.
   PubMed Web of Science ®Google Scholar
• Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med. 2010;16:543–552.
   PubMed Web of Science ®Google Scholar
• Morikawa T, Yasuno R, Wada H. Do mammalian cells synthesize lipoic acid? Identification of a mouse cDNA encoding a lipoic acid synthase located in mitochondria. FEBS Lett. 2001;498:16–21.
   PubMed Web of Science ®Google Scholar
• Padmalayam I, Hasham S, Saxena U, et al. Lipoic acid synthase (LASY): a novel role in inflammation, mitochondrial function, and insulin resistance. Diabetes. 2009;58:600–608.
   PubMed Web of Science ®Google Scholar
• Rago R, Marcucci I, Leto G, et al. Effect of myo-inositol and alpha-lipoic acid on oocyte quality in polycystic ovary syndrome non-obese women undergoing in vitro fertilization: a pilot study. J Biol Regul Homeost Agents. 2015;29:913–923.
   PubMed Web of Science ®Google Scholar
• Thomas RM, Nechamen CA, Mazurkiewicz JE, et al. The adapter protein APPL1 links FSH receptor to inositol 1,4,5-trisphosphate production and is implicated in intracellular Ca(2+) mobilization. Endocrinology. 2011;152:1691–1701.
   PubMed Web of Science ®Google Scholar
• De Cicco S, Immediata V, Romualdi D, et al. Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. Gynecol Endocrinol. 2017;33:698–701.
   PubMed Web of Science ®Google Scholar